May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
Iris Nodules Observed in Uveitides
Author Affiliations & Notes
  • D. Hayashi
    Ophthalmology, Tokyo Women's Medical University, Shinjyuku–ku, Japan
  • L. Chen
    Ophthalmology, Tokyo Women's Medical University, Shinjyuku–ku, Japan
  • M. Shimakawa
    Ophthalmology, Tokyo Women's Medical University, Shinjyuku–ku, Japan
  • S. Hori
    Ophthalmology, Tokyo Women's Medical University, Shinjyuku–ku, Japan
  • Footnotes
    Commercial Relationships  D. Hayashi, None; L. Chen, None; M. Shimakawa, None; S. Hori, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 5104. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. Hayashi, L. Chen, M. Shimakawa, S. Hori; Iris Nodules Observed in Uveitides . Invest. Ophthalmol. Vis. Sci. 2005;46(13):5104.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: This study is to find the differences in the clinical features and the therapeutics of iris nodules observed in uveitides. Methods: We retrospectively reviewed the clinical database of patients with uveitis at Tokyo women’s medical university during July, 2003 to October, 2004. 110 cases, 197 eyes of Sarcoidosis and 21 cases, 42 eyes of Vogt–Koyanagi–Harada syndrome(VKH), diagnosed according to each criteria, were identified, and the onset time, resolving periods, and therapeutics of iris nodules were compared. Results: 37 eyes(18.8%) of Sarcoidosis and 13 eyes(31%) of VKH with iris nodules were identified. 26 eyes(70.3%) of Sarcoidosis with iris nodules were observed on the first onset. On the other hand, all 13 eyes of VKH with iris nodules were observed on the recurrence, and there was a significant difference in onset time of iris nodule between Sarcoidosis and VKH(P<0.00002). Resolving periods of iris nodules after the medication were 2.1±0.2 weeks in Sarcoidosis and 5.0±1.0 weeks in VKH, which were significantly longer than Sarcoidosis(P<0.02). The resolving periods of iris nodules in VKH were 9.6±1.4 weeks with topical steroid alone, 5.8±2.0 weeks with systemic steroid, and 2.6±0.6 weeks with periocular steroid injection. Therefore, the resolving period of iris nodules was significantly shorter in periocular steroid injection than in topical steroid(P<0.05). Conclusions: Iris nodule in Sarcoidosis is more frequently observed on the first onset, while it is observed only on the recurrence in VKH. Also, the resolving period of iris nodule after the medication is shorter in Sarcoidosis than in VKH. Moreover, periocular steroid injection is the most effective therapeutics in VKH. Onset time and resolving period of iris nodules observed in uveitides vary due to the primary diseases; therefore, there is possibility of differences in the clinical aspects of iris nodules.

Keywords: uveitis-clinical/animal model • iris • injection 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×